Skip to main content

Table 2 Differential expression data for apolipoproteins in EV samples isolated by UC or NBI

From: Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis

Protein name

Accession number

UC, average LFQ(107)a

NBI, average LFQ(107)a

Fold change

UC/NBIb

Apolipoprotein A-I

APOA1_HUMAN

249 ± 21

57 ± 5.5

4.37*

Apolipoprotein A-II

APOA2_HUMAN

2.8 ± 0.4

0.1 ± 0.0

18*

Apolipoprotein A-IV

APOA4_HUMAN

6.9 ± 1.5

ND

–

Apolipoprotein B-100

APOB_HUMAN

628 ± 14

64 ± 8.2

9.8*

Apolipoprotein C-I

APOC1_HUMAN

0.6 ± 0.0

ND

–

Apolipoprotein C-II

APOC2_HUMAN

0.1 ± 0.0

ND

–

Apolipoprotein C-III

APOC3_HUMAN

4.0 ± 0.3

ND

–

Apolipoprotein D

APOD_HUMAN

4.7 ± 0.7

ND

–

Apolipoprotein E

APOE_HUMAN

7.0 ± 0.7

ND

–

Apolipoprotein L1

APOL1_HUMAN

0.4 ± 0.0

ND

–

Apolipoprotein M

APOLM_HUMAN

0.1 ± 0.0

ND

–

Apolipoprotein(a)

APOA_HUMAN

0.5 ± 0.1

ND

–

  1. (a) Label-free quantification (LFQ) based on average normalized peak intensity ± SEM of samples isolated by UC (3: #1UC, #2UC, #3UC) or NBI (3, #1NBI, #2NBI, #3NBI); (b) fold-changes in expression between the samples isolated by UC and NBI; *, p < 0.05, by Wilcoxon-Mann-Whitney test. ND not determined, proteins not found in NBI samples
Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326